WO1997006800A1 - Remede contre la nevrose d'angoisse - Google Patents
Remede contre la nevrose d'angoisse Download PDFInfo
- Publication number
- WO1997006800A1 WO1997006800A1 PCT/JP1996/002302 JP9602302W WO9706800A1 WO 1997006800 A1 WO1997006800 A1 WO 1997006800A1 JP 9602302 W JP9602302 W JP 9602302W WO 9706800 A1 WO9706800 A1 WO 9706800A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nicorandil
- anxiety
- acid
- salt
- omg
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 40
- 230000036506 anxiety Effects 0.000 claims abstract description 28
- 208000019906 panic disease Diseases 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- FCOXEIQHEDEXKV-UHFFFAOYSA-N nitric acid;pyridine-3-carboxamide Chemical compound O[N+]([O-])=O.NC(=O)C1=CC=CN=C1 FCOXEIQHEDEXKV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000009474 immediate action Effects 0.000 abstract 1
- 229960002497 nicorandil Drugs 0.000 description 40
- 239000003814 drug Substances 0.000 description 21
- 206010010904 Convulsion Diseases 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 206010008479 Chest Pain Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 7
- 206010033557 Palpitations Diseases 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- 239000002249 anxiolytic agent Substances 0.000 description 7
- 230000000949 anxiolytic effect Effects 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229960004404 etizolam Drugs 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 229940005530 anxiolytics Drugs 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010033664 Panic attack Diseases 0.000 description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 5
- 239000008116 calcium stearate Substances 0.000 description 5
- 235000013539 calcium stearate Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 4
- 229960004538 alprazolam Drugs 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940031652 nicorandil 10 mg Drugs 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- -1 pimephosphate Chemical compound 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000003204 tranquilizing agent Substances 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
- 206010003497 Asphyxia Diseases 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010066392 Fear of death Diseases 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010029333 Neurosis Diseases 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 238000010876 biochemical test Methods 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 229940125725 tranquilizer Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000007888 Sinus Tachycardia Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000000122 hyperventilation Diseases 0.000 description 2
- 230000000870 hyperventilation Effects 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004940 sulpiride Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000033042 Somatoform disorder cardiovascular Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000007657 cerebral ischemic lesion Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229960003829 desipramine hydrochloride Drugs 0.000 description 1
- XAEWZDYWZHIUCT-UHFFFAOYSA-N desipramine hydrochloride Chemical compound [H+].[Cl-].C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 XAEWZDYWZHIUCT-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960004843 mianserin hydrochloride Drugs 0.000 description 1
- YNPFMWCWRVTGKJ-UHFFFAOYSA-N mianserin hydrochloride Chemical compound [H+].[Cl-].C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 YNPFMWCWRVTGKJ-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 208000009157 neurocirculatory asthenia Diseases 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229940053982 other anxiolytics in atc Drugs 0.000 description 1
- 229950006124 oxazolam Drugs 0.000 description 1
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229960002835 trimipramine maleate Drugs 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the present invention relates to a therapeutic agent for anxiety neuropathy, which comprises N- (2-hydroxyethyl) nicotinamide nitrate or a salt thereof as an active ingredient, and particularly to an agent effective for treating panic disorder.
- Anxiety neurosis is a broad neurosis with anxiety as the main symptom.
- the American Psychiatric Association classified the conventional concept of anxiety neuropathy into panic disorder associated with panic attacks and generalized anxiety disorder, and summarized them in DSM-III.
- N- (2-hydroxyxethyl) nicotinamide nitrate (generic name: nicorandil) is a known compound that is marketed as an angina pectoris drug. It is described in Japanese Patent Publication No. 3 and the like. Nicorandil is known to have several effects in addition to its antianginal effect.For example, its effect as a therapeutic agent for circulatory diseases is disclosed in JP-A-53-93233, Are described in JP-A-58-85819. In addition, Japanese Patent Application Laid-Open Publication No. Sho 63-152352 / 17 discloses that nicorandil is useful as a therapeutic agent for diseases associated with cerebral ischemic lesions. Patent Publication No. 0 162 1 describes that nicorandil is useful as a hydroxyl radical scavenger. However, nicorandil and similar drugs have been used to treat anxiety disorders, especially panic disorders. It is not known to have any effect.
- tricyclic antidepressants which have been used to treat anxiety neuropathy, especially panic disorder, have a slow onset of action, as well as side effects due to anticholinergic effects such as ⁇ , constipation, and difficulty urinating. Also, the occurrence of serious side effects is a problem. Also, benzodiazepine anxiolytics are known to have hypersedation, withdrawal symptoms, drug dependence, muscle relaxant action, and the like. Therefore, there is a need for a drug that is highly safe and that prevents panic attacks and prevents or ameliorates remission or subsequent anxiety. Disclosure of the invention
- the present inventors have conducted intensive studies on a drug that has few side effects and is effective for anxiety disorders, particularly panic disorders. As a result, N- (2-hydroxyxethyl) nicotinamide nitrate or a salt thereof was found to be anxious. The present inventors have found that the present invention is effective not only for the prevention of neurosis but also for the subsequent occurrence of anxiety, leading to the present invention.
- N- (2-Hydroxityl) nicotinamide nitrate which is a medicinal component of the present invention, is a compound that is commercially available as a therapeutic agent for angina pectoris.
- the nicorandil tablet or the preparation for injection may be used as it is, but for example, the one produced by the method described in JP-A-52-122733 may be used.
- Nicorandil which is a medicinal ingredient used in the present invention, can form an acid addition salt with a pharmaceutically acceptable organic or inorganic acid, and these salts can also be used in the present invention.
- Such acid addition salts include, for example, hydrochloride, hydrobromide, phosphate, sulfate, nitrate, oxalate, lactate, tartrate, acetate, salicylate, benzoate, formate, Propionate, vivalate, getyl acetate, malonate, succinate, pimephosphate, fumarate, maleate, malate, sulfamate, phenylpropionate, Gluconate, ascorbate, isonicotinate, methanesulfonate, p-toluenesulfonate, quenze Acids, adipates or naphthalene disulfonates are exemplified.
- the anxiety neurosis in the present invention is a neurosis whose main symptom is anxiety, and is mainly composed of vague symptoms such as "somehow calm”, “somewhat frightening”, and “cannot stay still”.
- panic disorder can be defined as a disease having symptoms such as increased palpitations, finger tremor, loudness, sweating, frequent urination, and dyspnea.
- a disorder that is characterized by recurrent seizures, and has multiple symptoms of dyspnea, palpitations, sweating, suffocation, paresthesia, and other symptoms of fear of death and madness
- the medicament according to the present invention is useful as a therapeutic agent for anxiety disorders, especially panic disorders, but is also useful not only for the treatment of these diseases but also for the treatment and improvement of the above-mentioned symptoms caused by these diseases.
- nicorandil or a salt thereof when used as a therapeutic agent for anxiety disorder, particularly panic disorder, it is preferable to formulate and use it in an appropriate dosage form, for example, tablets, powders, granules, and fine granules. And capsules, injections, emulsions, suspensions, suppositories, transdermal absorbents and the like.
- Such preparations are described, for example, in JP-A-57-14559, JP-A-58-39618, JP-A-61-143316, JP-A-62 — 1 4 9 6 3 0 gazette, 6 2-16 1 7 2 7 gazette, 6 2-2 5 2 7 2 2 gazette, 6 2-2 5 2 7 2 3 gaz It can be produced by a method described in JP-A-63-27064.
- tablets include, for example, nicorandil or a salt thereof, an organic acid such as fumaric acid, oxalic acid, salicylic acid, tartaric acid, glutaric acid, and a saturated higher fatty acid which is solid at room temperature such as stearic acid and palmitic acid.
- a method of containing one or more of a mixture of saturated higher alcohols such as cetyl alcohol and stearyl alcohol, and a method of mixing fumaric acid and / or DL-tritophan with nicorandil or a salt thereof are exemplified.
- nicorandil or a salt thereof contains an alkali metal salt of an organic acid such as citric acid, fumaric acid, oxalic acid, malonic acid, maleic acid, and tartaric acid is used.
- organic acid such as citric acid, fumaric acid, oxalic acid, malonic acid, maleic acid, and tartaric acid.
- additional It is preferable to mix usual pharmaceutically acceptable carriers such as disintegrants, lubricants, binders, fragrances, coloring agents, and the like.
- Such carriers include lactose, corn starch, mannitol, kaolin, Crystalline cellulose, hydroxypropylcellulose, hydroquinpropylmethylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium, talc, croscarmellose sodium, anhydrous calcium hydrogen phosphate, calcium carbonate, calcium citrate, calcium stearate, magnesium stearate, etc.
- the dose of nicorandil or a salt thereof can be appropriately selected depending on the condition, body type, constitution, age, sex, administration route, dosage form, and the like of a target patient.
- the lower limit of the dose can be selected from the range of lmg to l5mg per day, preferably the range of 5 to 10mg, more preferably about 7.5mg, and the upper limit of the dose is 20mg to 80mg, preferably 25mg.
- the dose can be selected from the range of about 60 mg, more preferably about 3 Omg, and can be orally administered in 1 to 4 divided doses.
- the lower limit of the dose is 0.1 mg to 2 mg per day, preferably 0.5 mg to 6 mg, more preferably 1 mg to 2 mg per day.
- the upper limit can be selected from the range of 10 mg to 5 Omg, preferably the range of 20 mg to 3 Omg, more preferably about 24 mg, and can be administered in 1 to 4 divided doses.
- ⁇ 288 mg may be given as a continuous intravenous infusion.
- the nicorandil preparation of the present invention may further contain one or more other antidepressants, anxiolytics or other acceptable drugs, or may be used in combination with these drugs.
- the antidepressants mentioned here include, for example, imipramine hydrochloride, desipramine hydrochloride, trimipramine maleate, clomipramine hydrochloride, mianserin hydrochloride, amitributyline hydrochloride, maloptiline hydrochloride, sulpiride, etizolam, carbamazepine, etc.
- Anxiolytics include, for example, alprazolam, estazolam, oxazolam, diazepam, etc.
- other agents include, for example, sleeping pills such as triazolam, flunitrazepam, phenenolevital, zopiclone, and dimenhydrid.
- vasodilators such as diltiazem hydrochloride, difudipine hydrochloride, nitroglycerin, and isosorbide dinitrate.
- mannitol After 65.7 g of mannitol, 15 g of corn starch and 0.3 g of methylcellulose SM-400 (manufactured by Shin-Etsu Chemical) were thoroughly mixed in a mortar, water was added and kneaded. The kneaded product was sieved with a 30-mesh sieve and then dried at 45 ° C for 3 hours. The dried product was sieved and sized with 30 mesh to obtain a granulated product.
- methylcellulose SM-400 manufactured by Shin-Etsu Chemical
- Nicorandil 10 g, stearic acid 8 g sieved with 3 meshes, 81 g of granules and 1 g of magnesium stearate are mixed in a plastic bag, and a tablet weighs 10 Omg and is 2,000 in a mold having a diameter of 7 mm. It was tableted in the compression pressure of k cm 2.
- Nicorandil (10 g), granules (89 g), and calcium stearate (1 g) were mixed in a plastic bag, and the mixture was tableted in a mold having a weight of 10 Omg and a diameter of 7 mm at a compression pressure of 2000 kg / cm 2 .
- Nicorandil crystal 20 O g, lactose 1530 g, corn starch 200 g Add 60 g of ground fumaric acid powder (average particle size: about 3 zm) to a Shinagawa mixer, mix for 20 minutes, add 10 g of magnesium stearate, and mix for 1 minute.
- the mixed powder was compression-molded with a single-shot tableting machine in which a die having a diameter of 7 mm and a flat punch were set at a total pressure of about 1 ton so as to obtain 10 Omg per tablet.
- Nicorandil crystal 200 g, mannitol 880 g, carboxymethyl cell mouth — 100 g of scalcium, 800 g of salicylic acid crystal and 20 g of calcium stearate are uniformly mixed in a plastic bag. Granulate with a sieve to obtain slug granules. The slug granules were filled into a No. 3 capsule at 10 Omg.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU66705/96A AU710937B2 (en) | 1995-08-15 | 1996-08-15 | Remedies for anxiety neurosis |
US09/011,668 US5905086A (en) | 1995-08-15 | 1996-08-15 | Remedy for anxiety neurosis |
KR1019980701070A KR100325793B1 (ko) | 1995-08-15 | 1996-08-15 | 불안신경증치료제 |
EP96926649A EP0846465B1 (en) | 1995-08-15 | 1996-08-15 | Nicorandil against anxiety neurosis |
AT96926649T ATE228841T1 (de) | 1995-08-15 | 1996-08-15 | Nicorandil gegen angstneurosen |
DE69625210T DE69625210T2 (de) | 1995-08-15 | 1996-08-15 | Nicorandil gegen angstneurosen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/208048 | 1995-08-15 | ||
JP20804895 | 1995-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997006800A1 true WO1997006800A1 (fr) | 1997-02-27 |
Family
ID=16549788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/002302 WO1997006800A1 (fr) | 1995-08-15 | 1996-08-15 | Remede contre la nevrose d'angoisse |
Country Status (9)
Country | Link |
---|---|
US (1) | US5905086A (ja) |
EP (1) | EP0846465B1 (ja) |
KR (1) | KR100325793B1 (ja) |
AT (1) | ATE228841T1 (ja) |
AU (1) | AU710937B2 (ja) |
DE (1) | DE69625210T2 (ja) |
ES (1) | ES2187666T3 (ja) |
TW (1) | TW458776B (ja) |
WO (1) | WO1997006800A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532240A (ja) * | 1998-12-22 | 2002-10-02 | テトラ プロセス テクノロジー | 濾材システムの暗渠ブロック |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115661B1 (en) * | 1999-12-29 | 2006-10-03 | Queen's University At Kingston | Methods and compositions for mitigating pain |
JP2003523405A (ja) | 2000-02-22 | 2003-08-05 | セレジー カナダ インコーポレイテッド | 睡眠改善のための方法および組成物 |
US6906164B2 (en) * | 2000-12-07 | 2005-06-14 | Eastman Chemical Company | Polyester process using a pipe reactor |
JPWO2006004115A1 (ja) * | 2004-07-05 | 2008-04-24 | 中外製薬株式会社 | 過活動膀胱治療剤 |
FR2872705B1 (fr) * | 2004-07-08 | 2008-07-18 | Aventis Pharma Sa | Compositions contenant du nicorandil, procede de preparation et utilisation |
KR20150146125A (ko) | 2014-06-22 | 2015-12-31 | 이경록 | 다중 표시기능을 갖는 단일 정보표시등 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428039A (en) * | 1994-02-20 | 1995-06-27 | The Center For Innovative Technology | Method for electively achieving reversible hyperpolarized cardiac arrest |
-
1996
- 1996-08-13 TW TW085109827A patent/TW458776B/zh not_active IP Right Cessation
- 1996-08-15 EP EP96926649A patent/EP0846465B1/en not_active Expired - Lifetime
- 1996-08-15 WO PCT/JP1996/002302 patent/WO1997006800A1/ja active IP Right Grant
- 1996-08-15 AT AT96926649T patent/ATE228841T1/de not_active IP Right Cessation
- 1996-08-15 KR KR1019980701070A patent/KR100325793B1/ko not_active IP Right Cessation
- 1996-08-15 AU AU66705/96A patent/AU710937B2/en not_active Ceased
- 1996-08-15 DE DE69625210T patent/DE69625210T2/de not_active Expired - Fee Related
- 1996-08-15 ES ES96926649T patent/ES2187666T3/es not_active Expired - Lifetime
- 1996-08-15 US US09/011,668 patent/US5905086A/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
J. PHARMACOL. EXP. THER., 229(3), (1984), INOUE, T.; KANMURA, Y.; FUJISAWA, K.; ITOH, T.; KURIYAMA, H., "Effects of 2-Nicotinamidoethyl Nitrate (Nicorandil; SG-75) and its Derivatives on Smooth Muscle Cells of the Canine Mesenteric Artery", p. 793-802. * |
LIFE SCI., (1991), YAMORI, M.; GOMITA, Y.; OISHI, R., "Influence of Footshock Stress on Pharmacokinetics of Nicorandil in Rats", p. 2065-2073. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532240A (ja) * | 1998-12-22 | 2002-10-02 | テトラ プロセス テクノロジー | 濾材システムの暗渠ブロック |
JP4724300B2 (ja) * | 1998-12-22 | 2011-07-13 | セバーン トレント ウォーター ピュリフィケイション,インコーポレイテッド | 濾材システムの暗渠ブロック |
Also Published As
Publication number | Publication date |
---|---|
KR19990036401A (ko) | 1999-05-25 |
TW458776B (en) | 2001-10-11 |
EP0846465A1 (en) | 1998-06-10 |
EP0846465B1 (en) | 2002-12-04 |
ES2187666T3 (es) | 2003-06-16 |
DE69625210T2 (de) | 2003-08-14 |
AU710937B2 (en) | 1999-09-30 |
ATE228841T1 (de) | 2002-12-15 |
AU6670596A (en) | 1997-03-12 |
KR100325793B1 (ko) | 2002-06-20 |
US5905086A (en) | 1999-05-18 |
DE69625210D1 (de) | 2003-01-16 |
EP0846465A4 (en) | 1999-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0469605B2 (ja) | ||
US3282778A (en) | Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound | |
WO1997006800A1 (fr) | Remede contre la nevrose d'angoisse | |
Spiller et al. | Delayed onset of cardiac arrhythmias from sustained-release verapamil | |
US4800209A (en) | Method of alleviating withdrawal symptoms | |
EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
JP3947582B2 (ja) | 不安神経症治療剤 | |
KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
US20170087104A1 (en) | Medicament | |
JPS584718A (ja) | 新規適応症に用うる医薬製剤 | |
JP6042886B2 (ja) | 早漏症治療用の薬学組成物 | |
US3538224A (en) | Composition for treating human mental disorders | |
CN110279691A (zh) | 一种外科术后护理镇痛药物及其用途 | |
US3914425A (en) | Antitussive codeine composition | |
RU2183116C1 (ru) | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием | |
JPH04159224A (ja) | ヒトの糖尿病性知覚障害および末梢神経障害の治療剤 | |
US3491188A (en) | Pharmaceutical compositions and methods for the treatment of pain with combinations of thioridazine and imipramine,desipramine or pharmaceutically acceptable acid addition salts thereof | |
BRPI0617184A2 (pt) | formulação de pralnacasan com liberação retardada | |
Sedgwick et al. | Evaluation of pindolol in the treatment of hypertension | |
AU3484493A (en) | Brofaromine as an agent for treating post-traumatic stress | |
JPH1129476A (ja) | 麻薬依存抑制剤 | |
US3478151A (en) | Compositions of perphenazine and protriptyline for treating mental disorders | |
LONDON | Cardiovascular Risk Factors Identified in OSA | |
UA142574U (uk) | Спосіб лікування захворювань центральної нервової системи | |
JPH10287568A (ja) | アルコール依存症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CU CZ EE GE HU IL IS KE KG KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09011668 Country of ref document: US Ref document number: 1019980701070 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996926649 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996926649 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980701070 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980701070 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996926649 Country of ref document: EP |